Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBlue Cross Blue Shield OK Pathogen Panel Coverage …
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - OklahomaPolicy CPCPLABO4S

    Pathogen Panel Testing

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLABO4S alerts

    Get alerted when Policy CPCPLABO4S changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines outpatient lab management reimbursement criteria for pathogen panel tests and which panel types are reimbursable or non-reimbursable for Blue Cross Blue Shield of Oklahoma members and contracted providers.

    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyPathogen Panel Testing
    Policy CodePolicy CPCPLABO4S
    Change TypeCoverage revisioncoding updatesexclusions clarified
    Effective DateNov 7, 2025
    Last ReviewJul 25, 2025
    Next Review DateN/A
    Key ActionFor symptomatic outpatients, submit claims for panel testing of up to 5 respiratory pathogens only when clinical signs or symptoms of respiratory infection are documented.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Revised reimbursement language to allow panel testing of up to 5 respiratory pathogens (antigen or multiplex PCR) for individuals displaying signs and symptoms of a respiratory tract infection.

    Added and removed multiple temporary CPT/PLA (U) codes across updates (e.g., added 87428, 0556U, 0563U, 0564U, 0590U, 0593U; removed 0240U, 0241U, 0370U, 0373U, 0374U).

    Explicit non-reimbursement language added for molecular-based panel testing used for general screening of microorganisms (examples provided).

    up to 5max pathogens reimbursable (symptomatic)
    6+not reimbursable if
    multiplenon-reimbursable panel types
    12example codes listed
    outpatientsetting applicability

    Coverage Criteria for Outpatient Pathogen Panel Testing

    Outpatient pathogen panel coverage criteria

    Covered when ALL of the following outpatient-specific conditions are met:

    ALL of the following

    • Testing is performed in the outpatient setting (policy criteria do not apply to non-outpatient settings).
    • The individual is displaying signs and symptoms of a respiratory tract infection (see Note 1 for examples).
    • The test is an antigen test or multiplex PCR-based panel that includes no more than 5 respiratory pathogen targets.
    • Provider submits accurate documentation and uses valid HIPAA-approved code combinations; claims remain subject to code edit protocols, benefit coverage, provider contract language, and clinical payment and coding policies.

    ALL of the following

    • ONE OF

      • Antigen panel testing or multiplex PCR-based panel testing of 6 or more respiratory pathogens (panels with 6+ respiratory targets).
      • Multiplex PCR-based panel testing of pathogens in cerebrospinal fluid (CSF).
      • Molecular detection–based panel testing of pathogens in blood.
      • Molecular detection–based panel testing of urine pathogens for diagnosis of urinary tract infections (example: GENETWORx Molecular PCR UTI Test).
      • Molecular-based panel testing to screen for or diagnose wound infections (example: GENETWORx PCR Wound Testing).
      • Molecular-based panel testing used for general screening of microorganisms (example: MicroGenDX qPCR+NGS).

    Reimbursement criteria and exclusions

    Summary of reimbursement guidance, notable exclusions, and update-history items affecting outpatient multiplex/molecular panel testing:

    Allowance from update history: For individuals displaying signs and symptoms of a respiratory tract infection (Note 1), panel testing of up to 5 respiratory pathogens (antigen or multiplex PCR) may be reimbursed.
    Explicit exclusions added in history: Molecular-based panel testing used for general screening of microorganisms (examples called out: molecular vaginal swab panels, molecular urine panels, MicroGenDX qPCR+NGS, GENETWORx tests) is not reimbursable.
    Setting clarification: Reimbursement language was revised to apply specifically to the outpatient setting.
    Coding and effective-date notes: Multiple PLA/temporary CPT codes were added and removed across updates; providers should reference the policy history for specific codes and effective dates. Providers must submit accurate documentation and valid HIPAA-approved codes; claims are subject to code edit protocols and review.

    CPT/PLA/HCPCS Codes and Limits

    listed panel codes (not exhaustive)CPT
    0323U
    0371U
    0441U
    0442U
    0480U
    0504U
    0528U
    0531U
    0556U
    0563U
    1–10 of 13
    1/2
    Recent added and removed CPT/PLA codesmixed
    87428Added code (listed in update history)
    0556UAdded PLA/temporary code
    0563UAdded PLA/temporary code
    0564UAdded PLA/temporary code
    0590UAdded PLA/temporary code effective 10/1/2025
    0593UAdded PLA/temporary code effective 10/1/2025
    0240URemoved PLA/temporary code
    0241URemoved PLA/temporary code
    0370URemoved PLA/temporary code
    0373URemoved PLA/temporary code
    1–10 of 11
    1/2
    Additional historical code changesmixed
    0528UAdded new CPT/PLA code effective 01/01/2025 (history entry)
    0202UAdded code (history entry)
    0223UAdded code (history entry)
    0225UAdded code (history entry)
    0531UAdded code (history entry)
    0441UAdded code (history entry)
    0442UAdded code (history entry)
    0480UAdded code (history entry)
    0504UAdded code (history entry)
    0151URemoved code (history entry)
    1–10 of 11
    1/2
    inv-06: maximum_reimbursable_respiratory_panel_pathogens
    Maximum reimbursable respiratory pathogens per panel5
    Non-reimbursable threshold6 or more respiratory pathogens on a panel are not reimbursable
    Setting limitationApplies to outpatient testing only
    inv-07: max_panel_pathogens_allowed_for_reimbursement
    Maximum pathogens allowed for reimbursementUp to 5 respiratory pathogens per panel
    Panels exceeding limitPanels with 6 or more respiratory targets are not reimbursable

    Provider Documentation, Billing, and Reimbursement Notes

    Documentation Required

    Submit accurate documentation and use valid HIPAA‑approved codes

    Providers must submit accurate documentation of services performed and file claims using valid HIPAA‑approved code combinations. Claims are subject to code edit protocols, benefit coverage, provider contract language, medical policies, and clinical payment and coding policy review; providers may be asked to submit additional documentation upon request.

    Billing Rule

    Limited respiratory panels (≤5 targets) may be reimbursed for symptomatic patients

    For individuals displaying signs and symptoms of a respiratory tract infection (see Note 1), panel testing of up to 5 respiratory pathogens — either antigen testing or multiplex PCR‑based panel testing — may be reimbursed.

    • Maximum reimbursable panel size for symptomatic outpatient individuals: up to 5 respiratory pathogen targets

    Definitions and Symptom Details

    inv-11: respiratory_symptoms
    DefinitionSigns and symptoms of a respiratory tract infection
    ApplicabilityUsed to determine eligibility for limited respiratory panel reimbursement (see Note 1)
    SettingCriteria apply to individuals in the outpatient setting
    inv-12: respiratory_symptoms_detail
    Core adult symptomsFever; chills; fatigue; cough; rhinorrhea; anorexia; pharyngitis; vomiting; new ageusia or anosmia; headaches; myalgia; diarrhea; weakness
    Additional pediatric signsIrritability; decreased activity; nausea; rash; stomach pain; ear tugging/otalgia; vomiting after coughing; tachypnea; chest retractions/nasal flaring; grunting; wheezing; crackles; dehydration; cyanosis; apnea episodes; drooling; refusal to eat

    Policy Revision History

    2025-07-25revised_reimbursement

    Revised reimbursement language to state that for individuals displaying signs and symptoms of a respiratory tract infection, panel testing of up to 5 respiratory pathogens (antigen testing or multiplex PCR-based panel testing) may be reimbursed.

    2025-01-23codes_added

    Added temporary/PLA CPT codes 0202U, 0223U, 0225U, and 0531U (history entry noting addition on this date).

    2025-01-15code_effective_date
    Policy Summary
    PayerBlue Cross Blue Shield - Oklahoma
    PolicyPathogen Panel Testing
    Policy CodePolicy CPCPLABO4S
    Change TypeCoverage revisioncoding updatesexclusions clarified
    Effective DateNov 7, 2025
    Last ReviewJul 25, 2025
    Next Review DateN/A
    Key ActionFor symptomatic outpatients, submit claims for panel testing of up to 5 respiratory pathogens only when clinical signs or symptoms of respiratory infection are documented.
    SourceLink
    On This Page
    Coverage Criteria for Outpatient Pathogen Panel TestingCPT/PLA/HCPCS Codes and LimitsProvider Documentation, Billing, and Reimbursement NotesDefinitions and Symptom DetailsPolicy Revision History
    Test types covered by limitApplies to antigen testing or multiplex PCR-based panel testing
  1. Policy applies to outpatient testing only; clinical signs/symptoms must be present
  2. Denial Risk

    Do not bill for molecular general‑screening panels — not reimbursable

    Molecular‑based panel testing used for general screening of microorganisms is not reimbursable; examples include molecular panels of vaginal swabs, molecular testing on urine samples, GENETWORx Molecular PCR UTI Test, GENETWORx PCR Wound Testing, and MicroGenDX qPCR+NGS.

    • Non‑reimbursable use case: general screening of microorganisms (not diagnostic testing for symptomatic patients)
    • Examples listed in policy are not exhaustive but illustrative of non‑reimbursable screening panels
    Infant presentationsInfants may present with non-specific signs such as poor feeding, lethargy, and fussiness
    inv-13: Signs and symptoms of a respiratory tract infection (Note 1)
    Note 1 descriptionSigns and symptoms of a respiratory tract infection include fever, chills, fatigue, cough, rhinorrhea, anorexia, pharyngitis, vomiting, new ageusia or anosmia; pediatric signs may include irritability, decreased activity, nausea, rash, stomach pain, ear tugging/otalgia, vomiting after coughing, tachypnea, chest retractions/nasal flaring, grunting, wheezing, crackles, dehydration, cyanosis, apnea episodes, drooling, or refusal to eat; infants may present with non-specific signs such as poor feeding, lethargy, and fussiness.
    Purpose of Note 1Provides the clinical symptom list referenced to determine reimbursement eligibility for limited respiratory panels

    Added new CPT/PLA code 0528U effective 2025-01-01 (history entry recorded 11/19/2024 with effective date 01/01/2025).

    2024-10-30codes_added_removed

    Added codes 0441U, 0442U, 0480U, 0504U and removed codes 0151U and 0416U as part of reimbursement information updates.

    2024-11-01added_nonreimbursement_language

    Document updated with literature review clarifying that molecular-based panel testing used for general screening of microorganisms is not reimbursable.

    2025-01-23codes_added_future_effectiveLatest

    Added codes 87428, 0556U, 0563U, 0564U and added codes 0590U and 0593U with effective date 2025-10-01; removed codes 0240U, 0241U, 0370U, 0373U, and 0374U.